Mei‐Kuang Chen

2.1k total citations · 1 hit paper
24 papers, 1.2k citations indexed

About

Mei‐Kuang Chen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mei‐Kuang Chen has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mei‐Kuang Chen's work include PARP inhibition in cancer therapy (9 papers), Cancer-related Molecular Pathways (6 papers) and DNA Repair Mechanisms (4 papers). Mei‐Kuang Chen is often cited by papers focused on PARP inhibition in cancer therapy (9 papers), Cancer-related Molecular Pathways (6 papers) and DNA Repair Mechanisms (4 papers). Mei‐Kuang Chen collaborates with scholars based in United States, Taiwan and China. Mei‐Kuang Chen's co-authors include Mien‐Chie Hung, Jennifer L. Hsu, Jung-Mao Hsu, Yi Du, Hirohito Yamaguchi, Yongkun Wei, Gabriel N. Hortobágyi, Jennifer K. Litton, Wen-Hsuan Yu and Seung-Oe Lim and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mei‐Kuang Chen

24 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

2017 768 citations Shiping Jiao, Weiya Xia et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mei‐Kuang Chen United States	12	912	527	348	191	131	24	1.2k
Shiping Jiao China	6	917 1.0×	391 0.7×	401 1.2×	229 1.2×	127 1.0×	9	1.1k
Denarda Dangaj Laniti Switzerland	15	703 0.8×	367 0.7×	544 1.6×	78 0.4×	186 1.4×	31	1.1k
Kaiming Sun United States	9	685 0.8×	448 0.9×	268 0.8×	105 0.5×	78 0.6×	20	1.1k
Yang Peng United States	12	789 0.9×	906 1.7×	287 0.8×	146 0.8×	216 1.6×	27	1.4k
Lizhou Jia China	19	433 0.5×	468 0.9×	224 0.6×	123 0.6×	265 2.0×	45	968
Eileen E. Parkes United Kingdom	12	541 0.6×	441 0.8×	435 1.3×	157 0.8×	149 1.1×	36	1.0k
Takaaki Yasuhara Japan	12	663 0.7×	713 1.4×	311 0.9×	171 0.9×	128 1.0×	22	1.2k
Christine Alewine United States	18	517 0.6×	295 0.6×	395 1.1×	299 1.6×	97 0.7×	51	1.1k
Yuan Mao China	20	445 0.5×	497 0.9×	266 0.8×	123 0.6×	152 1.2×	58	946
Anna L Olsen United Kingdom	7	535 0.6×	727 1.4×	213 0.6×	50 0.3×	124 0.9×	9	964

Countries citing papers authored by Mei‐Kuang Chen

Since Specialization

Citations

This map shows the geographic impact of Mei‐Kuang Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Kuang Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Kuang Chen more than expected).

Fields of papers citing papers by Mei‐Kuang Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei‐Kuang Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Kuang Chen. The network helps show where Mei‐Kuang Chen may publish in the future.

Co-authorship network of co-authors of Mei‐Kuang Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Mei‐Kuang Chen. A scholar is included among the top collaborators of Mei‐Kuang Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei‐Kuang Chen. Mei‐Kuang Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Mei‐Kuang, et al.. (2025). Targeting CDK2 and other novel cell cycle targets for breast cancer therapy. Expert Opinion on Therapeutic Targets. 29(7). 435–456. 2 indexed citations

Li, Mi, Amriti R. Lulla, Spyros Tsavachidis, et al.. (2024). Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Research. 84(22). 3864–3880. 4 indexed citations

Salamanca, Eisner, et al.. (2024). Allylamine coating on zirconia dental implant surface promotes osteogenic differentiation in vitro and accelerates osseointegration in vivo. Clinical Oral Implants Research. 35(9). 1101–1113. 1 indexed citations

Mei, Ying, Qinglei Hang, Hongqi Teng, et al.. (2022). ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer. Genes & Diseases. 10(5). 1739–1742. 2 indexed citations

Shih, David, Mei‐Kuang Chen, Jun Yin, et al.. (2022). Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. PubMed. 12(1). 337–354. 1 indexed citations

Xue, Zhen, Shuang Zheng, Boning Liu, et al.. (2022). PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation.. PubMed. 12(5). 2363–2375. 13 indexed citations

Gao, Yuan, Mei‐Kuang Chen, Yu‐Yi Chu, et al.. (2021). Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.. American Journal of Cancer Research. 11(1). 236–250. 15 indexed citations

Chen, Mei‐Kuang, Yuan Gao, Dihua Yu, & Mien‐Chie Hung. (2021). Abstract LB097: MET inhibitor enhances efficacies of gemcitabine and olaparib in pancreatic cancer cells. Cancer Research. 81(13_Supplement). LB097–LB097. 1 indexed citations

Chen, Mei‐Kuang, Jennifer L. Hsu, & Mien‐Chie Hung. (2020). Nuclear receptor tyrosine kinase transport and functions in cancer. Advances in cancer research. 147. 59–107. 18 indexed citations

10.

Chu, Yu‐Yi, Clinton Yam, Mei‐Kuang Chen, et al.. (2020). Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.. PubMed. 10(2). 648–661. 36 indexed citations

11.

Sun, Xian Wen, Chia-Wei Li, Wei‐Jan Wang, et al.. (2020). Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.. American Journal of Cancer Research. 10(2). 564–571. 21 indexed citations

12.

Chen, Mei‐Kuang, et al.. (2020). Glow Discharge Plasma Treatment on Zirconia Surface to Enhance Osteoblastic-Like Cell Differentiation and Antimicrobial Effects. Materials. 13(17). 3771–3771. 11 indexed citations

13.

Chen, Mei‐Kuang, Yi Du, Linlin Sun, et al.. (2019). H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism. Journal of Biological Chemistry. 294(21). 8516–8528. 18 indexed citations

14.

Chen, Mei‐Kuang, Yi Du, Jennifer L. Hsu, et al.. (2019). Abstract 845: c-MET nuclear transportation via membrane-bounded retrograde trafficking in breast cancer cells. Cancer Research. 79(13_Supplement). 845–845. 1 indexed citations

15.

Han, Ye, Mei‐Kuang Chen, Jennifer L. Hsu, et al.. (2019). Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.. PubMed. 9(3). 608–618. 29 indexed citations

16.

Dong, Qiongzhu, Yi Du, Hui Li, et al.. (2018). EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research. 79(4). 819–829. 59 indexed citations

17.

Jiao, Shiping, Weiya Xia, Hirohito Yamaguchi, et al.. (2017). PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research. 23(14). 3711–3720. 768 indexed citations breakdown →

18.

Chen, Yi‐Chun, Yi Du, Zhenbo Han, et al.. (2017). A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma.. PubMed. 7(3). 657–672. 4 indexed citations

19.

Chen, Mei‐Kuang & Mien‐Chie Hung. (2015). Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS Journal. 282(19). 3693–3721. 64 indexed citations

20.

Chen, Mei‐Kuang, et al.. (2011). Delay of Gap Filling during Nucleotide Excision Repair by Base Excision Repair: The Concept of Competition Exemplified by the Effect of Propolis. Toxicological Sciences. 122(2). 339–348. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact